MicroVention’s LVIS EVO Intraluminal Support Device Launched in US

June 26, 2024—MicroVention, Inc. announced that its LVIS EVO intraluminal support device is commercially available in the United States for the treatment of wide-neck intracranial aneurysms.

The company stated that the LVIS EVO device is indicated for use with neurovascular embolization coils in patients ≥ 18 years of age for the treatment of wide-neck (neck width ≥ 4 mm or dome-to-neck ratio < 2) saccular intracranial aneurysms arising from a parent vessel with a diameter ≥ 2 and ≤ 4.5 mm.

LVIS EVO has been available in Europe since 2019, noted MicroVention, which is a subsidiary of Terumo Corporation.

According to MicroVention, LVIS EVO is a fully visible coil-assist intracranial stent that features DFT wire construction and advanced braid design. Other features of the device include the following:

• Wall apposition confirmation; the entire body of the stent is fully visible under fluoroscopy.
• Braid angle allows for improved device opening along the entire length of the device.
• Controlled delivery and development, as well as the ability to resheath the device up to 80% of the device length.

The entire LVIS EVO portfolio is compatible with MicroVention’s Headway 17 Advanced microcatheter and its Scepter C and Scepter XC occlusion balloons, advised the company.

“I’ve really enjoyed getting to use and know EVO,” commented Charles Matouk, MD, in MicroVention’s press release. “With improved visibility and the ability to shelf the stent across the aneurysm neck, it’s become my tool-of-choice for stent-assisted coiling.” Dr. Matouk is Vice Chair of the Department of Neurosurgery at Yale University in New Haven, Connecticut.